128 related articles for article (PubMed ID: 37431123)
1. Erythroderma with brentuximab vedotin in a patient with mycosis fungoides.
Kakurai M; Oya K; Ishizuki S; Suehara Y; Nomura T
Eur J Dermatol; 2023 Apr; 33(2):167-168. PubMed ID: 37431123
[No Abstract] [Full Text] [Related]
2. Poikilodermatous mycosis fungoides with CD30-positive large cell transformation successfully treated by brentuximab vedotin.
Popadic S; Lekic B; Tanasilovic S; Bosic M; Nikolic M
Dermatol Ther; 2020 Jan; 33(1):e13152. PubMed ID: 31743946
[TBL] [Abstract][Full Text] [Related]
3. An Elusive Case of Mycosis Fungoides: Case Report and Review of the Literature.
Pallazola VA; Deib G; Abha S; Geha RM; Kobayashi K
J Gen Intern Med; 2019 Nov; 34(11):2669-2674. PubMed ID: 31388911
[TBL] [Abstract][Full Text] [Related]
4. Exfoliative erythroderma. Skin biopsy is required to determine the cause of this pruritic eruption.
Levine N
Geriatrics; 2000 Aug; 55(8):25. PubMed ID: 10953683
[No Abstract] [Full Text] [Related]
5. New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia.
Pileri A; Starace M; Alessandrini A; Casadei B; Zinzani PL; Piraccini BM
Br J Dermatol; 2019 Jun; 180(6):1535-1536. PubMed ID: 30561000
[No Abstract] [Full Text] [Related]
6. [Pathogenesis and treatment of the erythrodermal form of mycosis fungoides].
Kalantaevskaia KA; Koziĭ LM
Vestn Dermatol Venerol; 1975 Dec; (12):3-8. PubMed ID: 132804
[No Abstract] [Full Text] [Related]
7. Dermoscopy as an auxiliary tool in the differentiation of the main types of erythroderma due to dermatological disorders.
Errichetti E; Piccirillo A; Stinco G
Int J Dermatol; 2016 Dec; 55(12):e616-e618. PubMed ID: 27420287
[No Abstract] [Full Text] [Related]
8. Guttate psoriasis in a patient with mycosis fungoides in treatment with Brentuximab vedotin: An unreported association.
Roccuzzo G; Cavallo F; Avallone G; Fava P; Conti L; Ribero S; Fierro MT; Quaglino P
Dermatol Ther; 2022 Apr; 35(4):e15309. PubMed ID: 35000253
[No Abstract] [Full Text] [Related]
9. Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.
Hofer V; Maurus K; Houben R; Schrama D; Roth S; Goebeler M; Geissinger E; Rosenwald A; Wobser M
J Cutan Pathol; 2022 Mar; 49(3):314-317. PubMed ID: 34854114
[No Abstract] [Full Text] [Related]
10. Dermatomyositis versus mycosis fungoides: Challenges in the diagnosis of erythroderma with associated myositis.
Masson A; Ram-Wolff C; Bouaziz JD; Cayuela JM; Lorillon G; Frumholtz L; Cassius C; Petit A; Léonard-Louis S; Battistella M; Vignon-Pennamen MD; Rivet J; Meignin V; Duverger L; Jachiet M; Bagot M; Lazaridou I
Ann Dermatol Venereol; 2023 Jun; 150(2):129-133. PubMed ID: 36682974
[No Abstract] [Full Text] [Related]
11. Diffuse alopecia areata induced by brentuximab vedotin therapy for advanced stage mycosis fungoides.
Canal-Garcia E; Alamon-Reig F; Combalia A
Dermatol Ther; 2022 May; 35(5):e15427. PubMed ID: 35262989
[No Abstract] [Full Text] [Related]
12. Effectiveness of brentuximab vedotin before and after allogeneic stem-cell transplantation in the management of transformed mycosis fungoides.
André R; Ram-Wolff C; Battistella M; Peffault de Latour R; Petit A; Bouaziz JD; Brice P; Bagot M; de Masson A
Br J Dermatol; 2020 Jun; 182(6):1503-1504. PubMed ID: 31854457
[No Abstract] [Full Text] [Related]
13. Safety and effectiveness of the combination of systemic gemcitabine and intralesional brentuximab vedotin in tumor-stage mycosis fungoides.
Torre-Castro J; Recio-Monescillo M; Castillo Bazan E; Díaz de la Pinta J; Rodríguez Pinilla M; Requena L; Córdoba R
Int J Dermatol; 2024 Jun; 63(6):828-830. PubMed ID: 38419393
[No Abstract] [Full Text] [Related]
14. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
[TBL] [Abstract][Full Text] [Related]
15. RF - Brentuximab as Treatment for CD30
Morgado-Carrasco D; Combalia A; Estrach Panella T
Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):769-770. PubMed ID: 31151669
[No Abstract] [Full Text] [Related]
16. Exfoliative, dermatitis, lymphoma, and mycosis fungoides.
Katz H; Binford R
Arch Dermatol; 1971 May; 103(5):558-9. PubMed ID: 4252990
[No Abstract] [Full Text] [Related]
17. Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.
Goyal A; Hordinsky M; Lazaryan A
Dermatol Ther; 2019 Mar; 32(2):e12835. PubMed ID: 30659762
[TBL] [Abstract][Full Text] [Related]
18. Ofuji papuloerythroderma associated with follicular mucinosis in mycosis fungoides.
Suh KS; Kim HC; Chae YS; Kim ST
J Dermatol; 1998 Mar; 25(3):185-9. PubMed ID: 9575682
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome.
Corbin ZA; Nguyen-Lin A; Li S; Rahbar Z; Tavallaee M; Vogel H; Salva KA; Wood GS; Kim YH; Nagpal S
J Neurooncol; 2017 May; 132(3):439-446. PubMed ID: 28271282
[TBL] [Abstract][Full Text] [Related]
20. Emergence of leprosy in a patient with mycosis fungoides.
Grossman D; Rapini RP; Osborne B; Duvic M
J Am Acad Dermatol; 1994 Feb; 30(2 Pt 2):313-5. PubMed ID: 8294589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
